SCHEMBL3086129

SCHEMBL3086129

CCOC(=O)C(Cc1ccc(OC(F)(F)F)cc1)C(=O)NS(=O)(=O)/C=C/c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.50
PPARG P37231 4/20 0.44
PPARA Q07869 4/20 0.44
EPHX2 P34913 2/20 0.44
PKM P14618 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 2/20 0.41
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
FPR2 P25090 1/20 0.39
KLKB1 P03952 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
HTT P42858 1/20 0.38
PPARD Q03181 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3086131 1.00 MMP8 (0.50) MMP8PPARGPPARAEPHX2PKM
SCHEMBL3103652 0.90 ITGB3 (0.45) PPARGPPARAEPHX2ALDH1A1POLB
SCHEMBL3103647 0.90 ITGB3 (0.45) PPARGPPARAEPHX2ALDH1A1POLB
SCHEMBL3090518 0.88 MMP8 (0.54) MMP8PPARGPPARAEPHX2PKM
SCHEMBL3090514 0.88 MMP8 (0.54) MMP8PPARGPPARAEPHX2PKM
SCHEMBL3085269 0.88 MMP8 (0.54) MMP8PPARGEPHX2PKMALDH1A1
SCHEMBL3085272 0.88 MMP8 (0.54) MMP8PPARGEPHX2PKMALDH1A1
SCHEMBL15000092 0.87 CNR2 (0.40) PPARGPPARAEPHX2ALDH1A1POLB
SCHEMBL15000095 0.87 CNR2 (0.40) PPARGPPARAEPHX2ALDH1A1POLB
SCHEMBL3085692 0.84 NR1H4 (0.41) PPARGPPARAEPHX2POLBITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MMP8 3060/4885PPARG 136/4885PPARA 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.